B-intervention	0	10	Gabapentin
O	11	14	for
B-condition	15	18	hot
I-condition	19	26	flashes
O	27	29	in
B-total-participants	30	33	420
O	34	39	women
O	40	44	with
O	45	51	breast
O	52	58	cancer
O	58	59	:
O	60	61	a
O	62	72	randomised
O	73	79	double
O	79	80	-
O	80	85	blind
O	86	93	placebo
O	93	94	-
O	94	104	controlled
O	105	110	trial
O	110	111	.

O	112	116	Most
O	117	122	women
O	123	132	receiving
O	133	141	systemic
O	142	149	therapy
O	150	153	for
O	154	160	breast
O	161	167	cancer
O	168	178	experience
O	179	182	hot
O	183	190	flashes
O	190	191	.

O	192	194	We
O	195	204	undertook
O	205	206	a
O	207	217	randomised
O	217	218	,
O	219	225	double
O	225	226	-
O	226	231	blind
O	231	232	,
O	233	240	placebo
O	240	241	-
O	241	251	controlled
O	251	252	,
O	253	258	multi
O	258	259	-
O	259	272	institutional
O	273	278	trial
O	279	281	to
O	282	288	assess
O	289	292	the
O	293	301	efficacy
O	302	304	of
O	305	315	gabapentin
O	316	318	in
O	319	330	controlling
O	331	334	hot
O	335	342	flashes
O	343	345	in
O	346	351	women
O	352	356	with
O	357	363	breast
O	364	370	cancer
O	370	371	.

B-total-participants	372	375	420
B-eligibility	376	381	women
I-eligibility	382	386	with
I-eligibility	387	393	breast
I-eligibility	394	400	cancer
I-eligibility	401	404	who
I-eligibility	405	409	were
I-eligibility	410	416	having
I-eligibility	417	420	two
I-eligibility	421	423	or
I-eligibility	424	428	more
I-eligibility	429	432	hot
I-eligibility	433	440	flashes
I-eligibility	441	444	per
I-eligibility	445	448	day
O	449	453	were
O	454	462	randomly
O	463	471	assigned
B-control	472	479	placebo
O	479	480	,
O	481	491	gabapentin
O	492	495	300
O	496	498	mg
O	498	499	/
O	499	502	day
O	502	503	,
O	504	506	or
O	507	517	gabapentin
O	518	521	900
O	522	524	mg
O	524	525	/
O	525	528	day
O	529	531	by
O	532	537	mouth
O	538	540	in
O	541	546	three
O	547	554	divided
O	555	560	doses
O	561	564	for
O	565	566	8
O	567	572	weeks
O	572	573	.

O	574	578	Each
O	579	586	patient
O	587	591	kept
O	592	593	a
O	594	595	1
O	595	596	-
O	596	600	week
O	600	601	,
O	602	606	self
O	606	607	-
O	607	613	report
O	614	619	diary
O	620	622	on
O	623	626	the
O	627	636	frequency
O	636	637	,
O	638	646	severity
O	646	647	,
O	648	651	and
O	652	660	duration
O	661	663	of
O	664	667	hot
O	668	675	flashes
O	676	682	before
O	683	686	the
O	687	692	start
O	693	695	of
O	696	699	the
O	700	705	study
O	706	709	and
O	710	716	during
O	717	722	weeks
O	723	724	4
O	725	728	and
O	729	730	8
O	731	733	of
O	734	743	treatment
O	743	744	.

O	745	753	Analyses
O	754	758	were
O	759	761	by
O	762	771	intention
O	772	774	to
O	775	780	treat
O	780	781	.

O	782	791	Evaluable
O	792	796	data
O	797	801	were
O	802	811	available
O	812	814	on
B-total-participants	815	818	371
O	819	831	participants
O	832	834	at
O	835	836	4
O	837	842	weeks
O	843	844	(
B-control-participants	844	847	119
O	848	855	placebo
O	855	856	,
B-intervention-participants	857	860	123
O	861	871	gabapentin
O	872	875	300
O	876	878	mg
O	878	879	,
O	880	883	and
B-intervention-participants	884	887	129
O	888	898	gabapentin
O	899	902	900
O	903	905	mg
O	905	906	)
O	907	910	and
B-total-participants	911	914	347
O	915	917	at
O	918	919	8
O	920	925	weeks
O	926	927	(
B-control-participants	927	930	113
O	931	938	placebo
O	938	939	,
B-intervention-participants	940	943	114
O	944	954	gabapentin
O	955	958	300
O	959	961	mg
O	961	962	,
O	963	966	and
B-intervention-participants	967	970	120
O	971	981	gabapentin
O	982	985	900
O	986	988	mg
O	988	989	)
O	989	990	.

O	991	994	The
O	995	1005	percentage
O	1006	1015	decreases
O	1016	1018	in
B-outcome	1019	1022	hot
I-outcome	1022	1023	-
I-outcome	1023	1028	flash
I-outcome	1029	1037	severity
I-outcome	1038	1043	score
O	1044	1051	between
O	1052	1060	baseline
O	1061	1064	and
B-outcome	1065	1070	weeks
I-outcome	1071	1072	4
I-outcome	1073	1076	and
I-outcome	1077	1078	8
O	1078	1079	,
O	1080	1092	respectively
O	1093	1097	were
O	1097	1098	:
B-cv-bin-percent	1099	1101	21
I-cv-bin-percent	1101	1102	%
O	1103	1104	(
O	1104	1106	95
O	1106	1107	%
O	1108	1110	CI
O	1111	1113	12
O	1114	1116	to
O	1117	1119	30
O	1119	1120	)
O	1121	1124	and
B-cv-bin-percent	1125	1127	15
I-cv-bin-percent	1127	1128	%
O	1129	1130	(
O	1130	1131	1
O	1132	1134	to
O	1135	1137	29
O	1137	1138	)
O	1139	1141	in
O	1142	1145	the
O	1146	1153	placebo
O	1154	1159	group
O	1159	1160	;
B-iv-bin-percent	1161	1163	33
I-iv-bin-percent	1163	1164	%
O	1165	1166	(
O	1166	1168	23
O	1169	1171	to
O	1172	1174	43
O	1174	1175	)
O	1176	1179	and
B-iv-bin-percent	1180	1182	31
I-iv-bin-percent	1182	1183	%
O	1184	1185	(
O	1185	1187	16
O	1188	1190	to
O	1191	1193	46
O	1193	1194	)
O	1195	1197	in
O	1198	1201	the
O	1202	1207	group
O	1208	1216	assigned
O	1217	1227	gabapentin
O	1228	1231	300
O	1232	1234	mg
O	1234	1235	;
O	1236	1239	and
B-iv-bin-percent	1240	1242	49
I-iv-bin-percent	1242	1243	%
O	1244	1245	(
O	1245	1247	42
O	1248	1250	to
O	1251	1253	56
O	1253	1254	)
O	1255	1258	and
B-iv-bin-percent	1259	1261	46
I-iv-bin-percent	1261	1262	%
O	1263	1264	(
O	1264	1266	34
O	1267	1269	to
O	1270	1272	58
O	1272	1273	)
O	1274	1276	in
O	1277	1280	the
O	1281	1286	group
O	1287	1295	assigned
O	1296	1306	gabapentin
O	1307	1310	900
O	1311	1313	mg
O	1313	1314	.

O	1315	1318	The
O	1319	1330	differences
O	1331	1338	between
O	1339	1342	the
O	1343	1349	groups
O	1350	1354	were
O	1355	1366	significant
O	1367	1368	(
O	1368	1369	p
O	1369	1370	=
O	1370	1371	0
O	1371	1372	.
O	1372	1376	0001
O	1377	1379	at
O	1380	1381	4
O	1382	1387	weeks
O	1388	1391	and
O	1392	1393	p
O	1393	1394	=
O	1394	1395	0
O	1395	1396	.
O	1396	1399	007
O	1400	1402	at
O	1403	1404	8
O	1405	1410	weeks
O	1411	1413	by
O	1414	1420	ANCOVA
O	1421	1424	for
O	1425	1432	overall
O	1433	1442	treatment
O	1443	1449	effect
O	1449	1450	,
O	1451	1459	adjusted
O	1460	1463	for
O	1464	1472	baseline
O	1473	1479	values
O	1479	1480	)
O	1480	1481	;
O	1482	1486	only
O	1487	1490	the
O	1491	1497	higher
O	1498	1502	dose
O	1503	1505	of
O	1506	1516	gabapentin
O	1517	1520	was
O	1521	1531	associated
O	1532	1536	with
O	1537	1548	significant
O	1549	1558	decreases
O	1559	1561	in
B-outcome	1562	1565	hot
I-outcome	1565	1566	-
I-outcome	1566	1571	flash
I-outcome	1572	1581	frequency
I-outcome	1582	1585	and
I-outcome	1586	1594	severity
O	1594	1595	.

O	1596	1606	Gabapentin
O	1607	1609	is
O	1610	1619	effective
O	1620	1622	in
O	1623	1626	the
O	1627	1634	control
O	1635	1637	of
O	1638	1641	hot
O	1642	1649	flashes
O	1650	1652	at
O	1653	1654	a
O	1655	1659	dose
O	1660	1662	of
O	1663	1666	900
O	1667	1669	mg
O	1669	1670	/
O	1670	1673	day
O	1673	1674	,
O	1675	1678	but
O	1679	1682	not
O	1683	1685	at
O	1686	1687	a
O	1688	1692	dose
O	1693	1695	of
O	1696	1699	300
O	1700	1702	mg
O	1702	1703	/
O	1703	1706	day
O	1706	1707	.

O	1708	1712	This
O	1713	1717	drug
O	1718	1724	should
O	1725	1727	be
O	1728	1738	considered
O	1739	1742	for
O	1743	1752	treatment
O	1753	1755	of
O	1756	1759	hot
O	1760	1767	flashes
O	1768	1770	in
O	1771	1776	women
O	1777	1781	with
O	1782	1788	breast
O	1789	1795	cancer
O	1795	1796	.
